JAC Advance Access published online on April 27, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki109
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Orthopaedic Surgery, University of Missouri, Columbia, MO, USA
* To whom correspondence should be addressed. Objectives: Staphylococcus aureus is the most common organism isolated in osteomyelitis. Methicillin-resistant S. aureus (MRSA) infections are particularly difficult to treat. We evaluated the efficacy of tigecycline and vancomycin with and without rifampicin in a rabbit model of MRSA osteomyelitis. Methods: A 28 day antibiotic therapy with a subcutaneous injection of tigecycline (14 mg/kg twice daily), with and without oral rifampicin (40 mg/kg twice daily); or subcutaneous administration of vancomycin (30 mg/kg twice daily), with and without oral rifampicin (40 mg/kg twice daily) were compared. Osteomyelitis was induced with an intramedullary injection of 106 colony-forming units of MRSA. Infected rabbits were randomly divided into six groups: tigecycline, tigecycline with oral rifampicin, vancomycin, vancomycin with oral rifampicin, and no treatment control and tigecycline bone penetration groups. Treatment began 2 weeks after infection. After 4 weeks of therapy, the rabbits were left untreated for 2 weeks. Rabbits were then euthanized, and the tibias were harvested. The bones were cultured, and bacterial counts of MRSA were performed. Results: Rabbits that received tigecycline and oral rifampicin therapy (n=14) showed a 100% infection clearance. Rabbits treated with tigecycline (n=10) showed a 90% clearance. Rabbits treated with vancomycin and oral rifampicin (n=10) also showed a 90% clearance. Rabbits treated with vancomycin (n=11) showed an 81.8% clearance. Untreated controls (n=15) demonstrated only a 26% clearance. For the tigecycline bone penetration group, the bone concentrations of tigecycline in the infected tibia were significantly higher than the non-infected ones. Conclusions: Tigecycline may be an effective alternative to vancomycin in the treatment of MRSA osteomyelitis.
Received October 6, 2004
Revised January 13, 2005
Accepted March 1, 2005
Original article
Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model
2 Infectious Diseases Unit, Department of Internal Medicine, San Bortolo Hospital, Vicenza, Italy
3 Department of Orthopedics and Rehabilitation, The University of Texas Medical Branch, Galveston, TX, USA
4 Department of Orthopaedic Surgery, University of Missouri, Columbia, MO, USA;
Jason H. Calhoun, E-mail: calhounj{at}health.missouri.edu
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Vaudaux, B. Fleury, A. Gjinovci, E. Huggler, M. Tangomo-Bento, and D. P. Lew Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3150 - 3152. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Bowker, A. R. Noel, and A. P. MacGowan Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4370 - 4373. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-Y. Yin, J. H. Calhoun, J. K. Thomas, S. Shapiro, and A. Schmitt-Hoffmann Efficacies of Ceftobiprole Medocaril and Comparators in a Rabbit Model of Osteomyelitis Due to Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1618 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Perlroth, M. Kuo, J. Tan, A. S. Bayer, and L. G. Miller Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature Arch Intern Med, April 28, 2008; 168(8): 805 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stanzani, F. Tumietto, M. B. Giannini, G. Bianchi, A. Nanetti, N. Vianelli, M. Arpinati, M. Giovannini, F. Bonifazi, G. Bandini, et al. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline J. Med. Microbiol., December 1, 2007; 56(12): 1692 - 1695. [Abstract] [Full Text] [PDF] |
||||



